Incyte : Retifanlimab Plus Chemotherapy Meets Primary Endpoint In Phase 3 SCAC Trial

Incyte's Phase 3 POD1UM-303/InterAACT 2 trial, published in The Lancet, demonstrated that retifanlimab (Zynyz) combined with carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal (SCAC), resulting in a 37% reduction in the risk of progression or death, with median PFS increasing to 9.3 months versus 7.4 months in the placebo group; this follows FDA approval of Zynyz in May 2025 for SCAC and submission for approval in Europe and Japan.

Analysis

Incyte Corporation's (INCY) recent publication in The Lancet of primary results from its Phase 3 POD1UM-303/InterAACT 2 trial for retifanlimab (Zynyz) marks a significant clinical advancement for the treatment of squamous cell carcinoma of the anal canal (SCAC). The study, involving adults with inoperable, locally recurrent, or metastatic SCAC not previously treated with systemic chemotherapy, successfully met its primary endpoint by showing a statistically significant improvement in progression-free survival (PFS). Specifically, the addition of retifanlimab to carboplatin and paclitaxel resulted in a clinically meaningful 37% reduction in the risk of progression or death, with patients achieving a median PFS of 9.3 months compared to 7.4 months for the placebo combination group. The company reports that the U.S. Food and Drug Administration (FDA) approved Zynyz in combination with platinum-based chemotherapy for this first-line indication in May 2025, and also granted approval for Zynyz as a single agent for certain SCAC patients with disease progression on or intolerance to platinum-based chemotherapy. Incyte is further pursuing market expansion, having submitted a Type II variation Marketing Authorization Application to the European Medicines Agency and having received acceptance in March 2025 of a Japanese New Drug Application by the Pharmaceuticals and Medical Devices Agency for retifanlimab in advanced SCAC, developments which underpin the strongly positive sentiment (0.85) for INCY.

Key Decisions for Investors

• The robust Phase 3 results for Zynyz, including a 37% reduction in progression risk and a 1.9-month median PFS benefit in SCAC, combined with its reported FDA approval in May 2025, significantly enhance Incyte's prospects in the oncology market.
• Investors should monitor the regulatory pathways for Zynyz with the European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency, as successful outcomes would materially expand its addressable market and revenue potential for Incyte.
• Given the positive clinical data and U.S. regulatory green light, Zynyz is positioned as an important treatment advancement for SCAC, and its commercial uptake following the reported May 2025 U.S. availability will be a key performance indicator for Incyte.